
Monobrite S 500mg/250mg Injection
Marketer
Zovaitalia Healthcare Pvt Ltd
Salt Composition
Ceftriaxone (500mg) + Sulbactam (250mg)
Overview Monobrite S 500mg/250mg Injection
Combiflox 500mg/250mg Injection, a dual-action antibiotic, is indicated for diverse bacterial infections. Its mechanism combats microbial proliferation, thereby limiting infection spread. Administration must be strictly under medical guidance; adherence to the prescribed schedule is crucial for efficacy. Treatment should be completed fully, regardless of symptom improvement, as premature cessation may compromise its effectiveness. Typical side effects include nausea, vomiting, diarrhea, and dyspepsia. Worsening side effects warrant immediate medical attention. Allergic reactions (rash, pruritus, edema, dyspnea) necessitate prompt medical help. Inform your physician of all current medications prior to commencing treatment. Pregnant or lactating individuals should seek medical counsel before use. Alcohol consumption should be avoided due to potential increased drowsiness. While generally non-impairing to driving ability, avoid driving if drowsiness or dizziness occurs. Adequate rest, a balanced diet, and ample hydration contribute to faster recovery. Monitoring may involve laboratory tests to assess treatment response.
Uses of Monobrite S 500mg/250mg Injection
Infections caused by bacteria
Major Benefits of Monobrite S 500mg/250mg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Monobrite S 500mg/250mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Monobrite S 500mg/250mg Injection:
This medication will be administered by your physician or their designated nurse; self-medication is strictly prohibited.
How Monobrite S 500mg/250mg Injection works:
Ceftriaxone and Sulbactam, combined as Monobrite S 500mg/250mg Injection, offer a dual-action antibacterial approach. Ceftriaxone, a cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering bacterial survival. Sulbactam, a beta-lactamase inhibitor, complements Ceftriaxone by counteracting bacterial resistance mechanisms, thereby boosting the antibiotic's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Monobrite S 500mg/250mg Injection and alcohol consumption.
PregnancySAFE IF PRESCRIBED
The injectable medication Monobrite S (500mg/250mg) is typically regarded as safe for pregnant individuals. Preclinical trials using animal models revealed minimal or no negative impacts on fetal development; however, data from human clinical trials remains scarce.
Breast feedingCAUTION
Administering Monobrite S 500mg/250mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment and until the medication is fully cleared from her system.
DrivingUNSAFE
The administration of Monobrite S 500mg/250mg Injection can lead to reduced awareness, visual disturbances, drowsiness, and dizziness. Driving should be avoided if any of these effects are experienced.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Monobrite S 500mg/250mg Injection to individuals with renal impairment. Physician consultation is advised.
LiverCAUTION
Patients with severe hepatic impairment should use Monobrite S 500mg/250mg Injection cautiously, potentially requiring dosage modification. Medical advice is recommended. Dosage alteration for Monobrite S 500mg/250mg Injection is unnecessary in individuals with mild to moderate liver dysfunction.
What if you forget to take Monobrite S 500mg/250mg Injection :
Omitting a scheduled dose of Monobrite S 500mg/250mg Injection warrants immediate physician consultation.
Facts to Know About Monobrite S 500mg/250mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobial Agents |
